Global Carcinoembryonic Antigen Cea Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2022 –2029 |
 Market Size (Base Year) |
USD 1,855.41 Million |
 Market Size (Forecast Year) |
USD 2,912.90 Million |
 CAGR |
% |
| Major Markets Players |
>全球癌胚抗原 (CEA) 市场，按测试类型（分子测试、血清学测试）、产品类型（CD66a、CD66b、CD66c、CD66d、CD66e、CD66f）、性别（男性、女性）、应用（胃肠道癌、结直肠癌、胰腺癌、乳腺癌、肺癌、甲状腺癌、卵巢癌、其他）、最终用户（医院、诊断中心、癌症中心、研究、学术机构）– 行业趋势和预测到 2029 年。
癌胚抗原 (CEA) 市场????分析和规模
早期结肠癌患者对癌胚抗原的敏感性较低。癌胚抗原 (CEA) 检测对直肠癌和大肠癌特别有用。癌胚抗原是世界上使用最广泛的肿瘤标志物之一。然而，它在结直肠癌中最为重要。
Data Bridge Market Research 分析，癌胚抗原 (CEA) 市场在 2021 年为 18.5541 亿美元，预计到 2029 年将达到 29.129 亿美元，在 2022 年至 2029 年的预测期内复合年增长率为 5.80%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。
癌胚抗原 (CEA) 市场范围和细分
|
报告指标 |
细节 |
|
预测期 |
2022 至 2029 年 |
|
基准年 |
2021 |
|
历史岁月 |
2020（可定制为 2014 - 2019） |
|
定量单位 |
收入（百万美元）、销量（单位）、定价（美元） |
|
涵盖的领域 |
检测类型（分子检测、血清学检测）、产品类型（CD66a、CD66b、CD66c、CD66d、CD66e、CD66f）、性别（男、女）、应用（胃肠癌、结直肠癌、胰腺癌、乳腺癌、肺癌、甲状腺癌、卵巢癌、其他）、最终用户（医院、诊断中心、癌症中心、研究、学术机构） |
|
覆盖国家 |
北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲 (MEA) 的其他地区、巴西、阿根廷和南美洲的其他地区。 |
|
涵盖的市场参与者 |
Quest Diagnostics Incorporated (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Genway Biotech, LLC. (U.S.), Abbott (U.S.), Mayo Foundation for Medical Education and Research (MFMER) (U.S.), Lee BioSolutions (U.S.), RayBiotech Life, Inc (U.S.), Correlogic Systems, Inc. (Hong Kong), Boster Biological Technology (U.S.), Omega Diagnostics Group PLC (U.K.), Creative Diagnostics (U.S.), Cigna (U.S.), Merck KGaA (Germany), Prospec-Tany Technogene Ltd (Israel), Laboratory Corporation of America Holdings (U.S.) |
|
Market Opportunities |
|
Market Definition
Carcinoembryonic antigen (CEA) is found in embryonic endodermal epithelial cells. Carcinoembryonic antigen is a glycoprotein found in the fluids of the foetus and embryo, as well as the gastrointestinal tract. Carcinoembryonic antigen is also found in colorectal mucosal cells, gastrointestinal cells, and in trace amounts in the blood. The test is also to manage and diagnose cancers such as breast cancer, colorectal or colon cancer, gastrointestinal cancer, liver cancer, ovarian cancer, lung cancer, and others.
Global Carcinoembryonic Antigen (CEA) Market Dynamics
Drivers
- Rising awareness to bolster the growth
Increasing awareness about preclinical testing for disease detection, but carcinoembryonic antigen is the most cost-effective valuation, which continues to drive market demand for testing. Furthermore, consumers' rising disposable income, combined with rising life expectancy, will eventually result in market growth. Favourable government policies relating to cancer awareness and control implemented by organisations such as the National Cancer Institute and (CPCRN) are boost market growth.
- Technological developments
Proteomics-related technological advancements, such as protein bioinformatics, mass spectroscopy, protein labelling, imaging, and array-based approaches, are drive market growth. The development of new biomarkers and immunological techniques such as radioimmunoassay that can be used in conjunction with carcinoembryonic antigen (CEA) for the detection of various types of cancers will also drive market growth. For instance, the development of tumour markers that can be used in conjunction with CEA to detect colorectal cancer. Government initiatives to introduce new diagnostic tools/technologies are drive market growth. Furthermore, rising demand for minimally invasive diagnostic procedures to avoid various post-procedural side effects drives the growth of this market.
- Increasing number of cancer cases
According to the World Health Organization, cancer is one of the leading causes of death worldwide. It is expected to cause 10 million deaths by 2020. Cancer is responsible for approximately one in every six deaths worldwide. Cancer kills approximately 70% of people in low- and middle-income countries; the most common types of cancer are breast (2.26 million cases in 2020), lung (2.21 million cases in 2020), and colon and rectum cancers (1.93 million cases in 2020). The number of cancer cases diagnosed each year in the world has increased dramatically due to increased life expectancy, resulting in millions of people being diagnosed in their lifetime, driving the market's growth.
Opportunities
- Rise in the number of hospitals in the developing economies
Cancer has become the leading cause of death in many parts of the world due to rapid growth in the number of cancer patients and cancer incidences in both developed and developing countries. According to the WHO, nearly 10 million deaths occur each year as a result of cancer, with 1.93 million cases of colon and rectum cancer in 2020. Healthcare services are improving and focusing on earlier disease detection and treatment. Population growth and increased life expectancy are the primary factors driving the overall increase in incidence. Furthermore, rising public awareness of cancer has increased the number of patients who undergo screening.
- Increasing prevalence of unhealthy lifestyles
The increasing prevalence of unhealthy lifestyles such as irregular dietary habits and exposure to carcinogenic elements all contribute to its large share. Furthermore, increased alcohol consumption and sedentary lifestyle may contribute to the growth of colorectal cancer over the next seven years.
Restraints/Challenges
- Risk of infection will restrain the growth
Dearth of awareness about the carcinoembryonic antigen test, risk of infections by carcinoembryonic antigen testing and failure to detect cancer at the initial stage will obstruct the market's growth rate.
This carcinoembryonic antigen (CEA) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the carcinoembryonic antigen (CEA) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on the Carcinoembryonic Antigen (CEA) Market
COVID-19 为癌胚抗原 (CEA) 市场创造了新的机会。例如，COVID-19 迫使我们专注于生物技术改良产品，以取得更好的效果。在疫情期间，许多生物制药公司开发了生物技术改良疫苗和诊断试剂盒来治疗 SARS-CoV-2。此外，生物技术设备在疫情的各个阶段都发挥了作用；COVID-19 疫情让我们意识到，生物技术解决方案可以提供更好的医疗保健系统，对癌胚抗原 (CEA) 市场产生积极影响。
全球癌胚抗原 (CEA) 市场范围
癌胚抗原 (CEA) 市场根据检测类型、产品类型、性别、应用和最终用户进行细分。这些细分市场之间的增长将帮助您分析行业中增长缓慢的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策以确定核心市场。
测试类型
- 分子检测
- 血清学检测
产品类型
- CD66a
- CD66b
- CD66c
- CD66d
- CD66e
- CD66f
性别
- 男性
- 女性
应用
终端用户
- 医院
- 诊断中心
- 癌症中心
- 研究
- 学术机构
癌胚抗原 (CEA) 市场区域分析/见解
对癌胚抗原 (CEA) 市场进行了分析，并按国家、测试类型、产品类型、性别、应用和最终用户提供了市场规模洞察和趋势。
癌胚抗原 (CEA) 市场报告涵盖的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。
由于北美癌症发病率高、医疗保健基础设施完善、患者认知水平高，北美在癌胚抗原 (CEA) 市场占据主导地位。
由于患者意识的不断增强、癌症发病率高以及该地区拥有先进的医疗保健框架，预计亚太地区将在 2022 年至 2029 年的预测期内实现最高增长率。
报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
医疗保健基础设施增长安装基础和新技术渗透
癌胚抗原 (CEA) 市场还为您提供详细的市场分析，包括每个国家/地区资本设备医疗保健支出的增长、癌胚抗原 (CEA) 市场不同类型产品的安装基数、使用生命线曲线的技术的影响以及医疗保健监管情景的变化及其对癌胚抗原 (CEA) 市场的影响。数据适用于 2010-2020 年的历史时期。
竞争格局和癌胚抗原 (CEA) 市场份额分析
癌胚抗原 (CEA) 市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对癌胚抗原 (CEA) 市场的关注有关。
癌胚抗原 (CEA) 市场的一些主要参与者包括：
- Quest Diagnostics Incorporated（美国）
- F. Hoffmann-La Roche Ltd（瑞士）
- Genway Biotech, LLC.（美国）
- 雅培（美国）
- 梅奥医学教育与研究基金会（MFMER）（美国）
- Lee BioSolutions（美国）
- RayBiotech Life, Inc（美国）
- Correlogic Systems, Inc. (香港)
- 博士德生物技术公司（美国）
- Omega Diagnostics Group PLC（英国）
- Creative Diagnostics（美国）
- Cigna (美国)
- 默克集团（德国）
- Prospec-Tany Technogene Ltd（以色列）
- 美国实验室控股公司（美国）
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
